Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

RP-3500

Catalog No: tcbc074297

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Specifications

CAS No:
2417489-10-0

Formula:
$C_{21}H_{26}N_6O_3$

Target:
ATM/ATR

Purity / Grade:
>98% (HPLC)

Solubility:
10 mM in DMSO

Storage Instruction:
Solid Form: -20°C for 12 Months; 4°C for 6 Months In Solvent: -80°C for 6 Months; -20°C for 6 Months

Alternative Names:
(1R,3r,5S)-3-(6-((R)-3-methylmorpholino)-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-8-oxabicyclo[3.2.1]octan-3-ol

Calculated Molecular Weight:
410.478

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

References

Anne Roulston, et al. Mol Cancer Ther. 2022 Feb;21(2):245-256.

Product Description

RP-3500 (RP3500) is a novel potent, selective, orally bioavailable ATR inhibitor with IC50 of 1.0 and 0.33 nM in biochemical and cell-based assays, respectively.

RP-3500 displays 30-fold selectivity over mTOR and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases.

RP-3500 inhibited phosphorylated checkpoint kinase 1 (pCHK1) (IC80=18.6 nM) and induction of phosphorylated H2A.X variant histone (γH2AX), phosphorylated DNA-PK catalytic subunit (pDNA-PKcs), and phosphorylated KRAB-associated protein 1 (pKAP1).

RP-3500 demonstrated potent single-agent efficacy and/or tumor regression in multiple xenograft models at minimum effective doses (MED) of 5 to 7 mg/kg once daily.

RP-3500 demonstrated superior efficacy when combined with PARP inhibitor olaparib or niraparib.